BioNTech registers two first-in-human trials: BNT3219 and BNT3210 in advanced solid tumors

BioNTech's registry activity for the week includes two newly posted early-stage oncology trials.

• BNT3219, also known as PM1092, is being tested in a Phase I/Ib trial for advanced solid tumors, registered as NCT07893054 with status "not yet recruiting." The study will test BNT3219 in adults with advanced solid tumors whose cancer has progressed after available standard treatments, and it is the first study of BNT3219 in people, testing different dose levels to identify safe and tolerable doses.¹ The trial lists an estimated enrollment of 207 participants¹, with BioNTech SE as lead sponsor and BioNTech (Shanghai) Pharmaceuticals Co., Ltd. as a collaborator.
• BNT3210 is being tested in a Phase I/II trial for advanced solid tumors expressing the tumor marker Sialyl-Tn, registered as NCT07886684 with status "not yet recruiting." The study is the first time BNT3210 will be tested in people, evaluating different dose levels to find suitable doses and understand safety and potential benefit.² The trial lists an estimated enrollment of 173 participants², also sponsored by BioNTech SE with BioNTech (Shanghai) Pharmaceuticals Co., Ltd. as a collaborator.